Genotype–phenotype correlations in CPT1A deficiency detected by newborn screening in Pacific populations

• Published in: JIMD Reports
• Main Authors: Bernhardt, Isaac, Glamuzina, Emma, Dowsett, Leah K., Webster, Dianne, Knoll, Detlef, Carpenter, Kevin, Bennett, Michael J., Maeda, Michelle, Wilson, Callum
• Format: Text
• Language: English
• Published: John Wiley & Sons, Inc. 2022
• Subjects: Research Reports; Arctic; New Zealand; Pacific; Climate change; inuit
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259392/; http://www.ncbi.nlm.nih.gov/pubmed/35822099; https://doi.org/10.1002/jmd2.12271

Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a long chain fatty acid oxidation disorder, typically presenting with hypoketotic hypoglycaemia and liver dysfunction during fasting and intercurrent illness. Classical CPT1A deficiency is a rare disease, although a milder ‘Arctic variant' (p.P479L) is common in the Inuit population. Since the introduction of expanded metabolic screening (EMS), the newborn screening programmes of Hawai'i and New Zealand (NZ) have detected a significant increase in the incidence of CPT1A deficiency. We report 22 individuals of Micronesian descent (12 in NZ and 10 in Hawai'i), homozygous for a CPT1A c.100T>C (p.S34P) variant detected by EMS or ascertained following diagnosis of a family member. No individuals with the Micronesian variant presented clinically with metabolic decompensation prior to diagnosis or during follow‐up. Three asymptomatic homozygous adults were detected following the diagnosis of their children by EMS. CPT1A activity in cultured skin fibroblasts showed residual enzyme activity of 26% of normal controls. Secondly, we report three individuals from two unrelated Niuean families who presented clinically with symptoms of classic CPT1A deficiency, prior to the introduction of EMS. All were found to be homozygous for a CPT1A c.2122A>C (p.S708R) variant. CPT1A activity in fibroblasts of all three individuals was severely reduced at 4% of normal controls. Migration pressure, in part due to climate change may lead to increased frequency of presentation of Pacific peoples to regional metabolic services around the world. Knowledge of genotype–phenotype correlations in these populations will therefore inform counselling and treatment of those detected by newborn screening.